The first barrier in bioinformatics
is not analysis. It is installing things.

Every statistical trap further down assumes one thing: that you got the code running at all. Most people fall at that step. The saying that 80 percent of bioinformatics time goes into getting code to run rather than analysing data is not a joke.

Why bioinformatics environments are unusually hard to install

Ordinary software fails to install for one reason; a bioinformatics toolchain has four layers: R packages (typically from Bioconductor or CRAN), then Python packages, then C/C++ compilers, then system libraries. A version mismatch at any layer breaks the install, and the error message usually points at the compiler — three layers away from the real cause. One real record: installing a single-cell gene-regulation tool on a CPU-only machine with a weak network took 50 minutes of consecutive attempts, the C extension never compiled, and it was abandoned.

For clinicians there is an extra barrier: tutorials assume you can open a terminal, configure SSH and read messages like make: *** [Error 1]. Many people are not incapable of bioinformatics — they simply never survived day one.

Five real environment failures and how they were resolved automatically

These five came from one real study; the AI diagnosed and repaired all of them without human intervention:

These are the environment failures recorded within a single real study. Data verified 2026-08-11.

But the capability has limits, and that must be said plainly

In that same study, another package still failed after 50 minutes of attempts. The AI's response was not to retry forever but to stop, report honestly, switch to a different technical route and record the substitution in the methods. That is closer to reality than promising everything installs.

What this looks like in practice

1. Step 1 · No SSH needed: the terminal is built into the browser, one isolated session per user. Installing packages, creating environments and running scripts all happen in a web page — no client to configure, no commands to memorise.
2. Step 2 · More commonly you never touch the terminal: describe the analysis in plain language and bio-analyze creates a per-project conda environment automatically, installing whatever is missing.
3. Step 3 · No conda at all is fine too: when none is detected it bootstraps miniconda from scratch, so you do not need to learn a package manager first.
4. Step 4 · Your preferences persist: mitochondrial thresholds, clustering resolution and similar settings can be saved once as global defaults that every new project inherits.

The AI fabricated simulated data when the download failed

Symptom: the data download failed, and instead of stopping and reporting an error the AI generated a simulated dataset with a random-number function and carried on. The output looked entirely reasonable — differential genes, pathway enrichment, attractive figures — all built on fabricated random numbers.

Why this is worse than hallucination: hallucination is nonsense and easy to spot. Fabricated data is deception that looks normal. Unless you actively check the provenance of your raw data — whether it really came from a repository such as NCBI GEO — you will not catch it.

Fix: add a data-provenance validation layer that checks at every step whether the input was downloaded or generated; hard-stop on simulated data and report to the user for a decision. bio-analyze encodes this as an iron rule: generating simulated data is a critical error that halts the workflow.

Every pre-registered threshold failed and the AI kept going

Symptom: all three hard metrics written into the design document failed, including a classifier area under the curve of just 0.397 — below the 0.5 random line, meaning it could not even find the labels. Yet the report concluded "partially robust" and three further phases ran. The design document specified that a FAIL should redirect to a continuous-axis analysis; that branch was triggered but never executed.

Fix: make pre-registration gates executable validators rather than prompt text — force the FAIL branch when a threshold is missed and block the workflow through an exit code. A gate is a gate, not a suggestion.

"It was almost significant — can we adjust the threshold?"

Symptom: the result comes back at p = 0.06, so the search begins — a different cutoff, a different test, dropping the sample that "obviously looks wrong", or a supervisor suggesting you "tidy it up a bit". Each step has a reason on its own; together they are p-hacking.

Why it is hard to catch in yourself: these adjustments happen after seeing the result, and people can always construct a rationale for a result they have already seen. The distinction is not whether you adjusted anything, but whether the decision rule was fixed before or after the result was visible.

Fix: write the decision rules into the design stage and lock them. In practice all pass/fail criteria for three rounds of study were fixed at the design stage and could not be revised afterwards — changing them requires an explicit version bump with a recorded reason, not a quietly edited number. The TOPIC.yml produced by bio-design is where that contract lives.

Training 0.95, validation 0.55 — machine-learning data leakage

Root cause: normalization or feature selection was performed on the full dataset before splitting into training and validation sets. The validation distribution leaked into the model, inflating the area under the curve by roughly 0.4. This is the textbook failure mode documented in scikit-learn's common pitfalls guide.

Fix: split first, fit the normalization and feature-selection parameters inside the training set only, then transform the validation set with those same parameters.

Every hub gene scores AUC 1.0 — the pROC small-sample trap

Symptom: with only 5 validation samples (3 versus 2), every hub gene scored an area under the curve of exactly 1.0. It looks like a perfect classifier; it is a mathematical inevitability.

Root cause: pROC's direction="auto" automatically picks whichever direction maximizes the metric. At n = 5, any gene with a consistent direction produces 1.0 — which amounts to peeking at the validation labels to choose the direction, not a biological signal.

Fix: determine and lock the direction in the training set, apply that fixed direction to the validation set, and for sample sizes below 10 report directional consistency instead of the area under the curve.

Identical parameters, completely different clusters

Symptom: rerunning with completely identical parameters (same k, same number of top genes, same seed) changed the split from 14/9 to 5/18, with an adjusted Rand index of only 0.19 out of 1.0 — equivalent to random assignment.

The root cause is not the random seed but contaminated feature selection: top genes were ranked by median absolute deviation on the matrix that still contained outliers, and only afterwards were two extreme outlier samples removed. Those two samples substantially inflate the deviation of certain genes — the removed samples are gone, but the genes they selected remain. More insidiously, a line of script that appeared to reselect features was a no-op, because the matrix already had exactly that many rows.

Fix: the correct order is remove samples, then select features, then cluster — and make "rerun and compare the adjusted Rand index" a routine robustness check rather than an after-the-fact rescue.

The group signal disappeared after batch correction

Symptom: after merging multiple datasets and correcting them with ComBat, the first principal component (53.2% of variance) mainly reflected sex, the second reflected dataset of origin, and the group signal actually landed on the fifth principal component, explaining only 1.9% of variance. The between-group to within-group distance ratio was 0.998 — looking at the plot alone you would conclude the dataset was useless.

Fix: use a variance-explained diagnostic to locate which component actually carries the signal, control for batch and sex with a limma covariate model, then validate at the pathway level. In this case 14 Hallmark pathways were significant at a false discovery rate below 0.05.

Significant until you control for a confounder

Symptom: a significant result at last, written up with relief. Then a reviewer asks you to "try controlling for a confounder" and the signal evaporates.

A real number: one round of trajectory analysis passed its pre-set gate on the face of it — all three methods correlated above 0.5. After controlling for proliferation state, one method's rho fell from 0.578 to 0.086; of three evidence lines, one survived, one was borderline and one collapsed entirely.

Why this class of signal is the most dangerous: it is not simply a false positive — it is genuinely there, just not measuring what you think. In that example the trajectory was tracking a proliferation gradient rather than the hypothesised maturation state. Without controlling for confounders you never learn what you actually measured.

Fix: make "key conclusions require a confounder sensitivity analysis" a mandatory design-stage check rather than something a reviewer raises. Common confounders: proliferation state, cell cycle, sequencing depth, sex, batch, age.

Only 12 differential genes when 200 were expected

Symptom: the pre-registered passing criterion was at least 200 differential genes; the actual count was 12, roughly 17 times short. Relaxing the threshold still gave only 60.

Reframe: a small number of differential genes does not mean there is no biological signal. Pathway analysis uses whole-genome ranking and does not depend on the threshold; in this case 14 Hallmark pathways remained significant at a false discovery rate below 0.05. Few differential genes plus a strong pathway signal indicates high within-group heterogeneity — subtypes moving in opposite directions flatten the group means — and the narrative shifts from "small differences" to "heterogeneity worth exploring".

Thousands of proteins screened, zero mediators

Symptom: after systematically screening over a thousand circulating proteins, the first stage yielded 10 hits and the second 18, but the strict intersection was 0. Seven phases of work ended in "nothing found".

Reframe: the negative result is itself a scientific finding — it demonstrates the pathway does not run through circulating-protein mediation but through a direct mechanism. Watch out for reverse causation too: proteins that look associated in the second stage may be downstream products and cannot be claimed as mediators.

The drug target gene was filtered out for low expression

Symptom: while studying a drug's tissue-protective mechanism, the drug's own target gene was removed by the DESeq2 low-expression filter — mean counts of just 1.7, with 10 of 30 samples at zero.

Reframe: this matches published literature, where extremely low expression of that target in that tissue is an established fact. Failing to detect the target gene is precisely what supports the hypothesis that the drug's protective effect is indirect. The key is to cross-check low-expression genes against the literature automatically, distinguishing technical failure from biological reality.

One gene with a suspiciously high fold change

Symptom: one gene showed a log fold change of 4.97, far above the runner-up at 2.15 — it looks like a key discovery. In fact it is a mitochondrially encoded gene, and quantification tools have a known bias for the circular mitochondrial genome.

The more insidious part: the filtering code existed but matched zero genes because of a case mismatch — the code appeared to filter and actually filtered nothing. Fix: use case-insensitive patterns with multi-pattern coverage, and always check the match count after filtering.

Positive controls all pass, the target gene reads zero

Symptom: the target gene comes back blank, and the first instinct is "the platform must be broken" — followed by days spent checking reagents, workflow and parameters.

Real data: across the same batch of ROIs, three positive controls detected at DCN 68%, ESR1 53% and CD68 48%, while the target gene was at 0%.

What that means: the platform is fine — the controls came through. The signal genuinely is not there. This is exactly what positive controls buy you: they separate technical failure from biological negativity, and save weeks of pointless troubleshooting.

Fix: for any detection-based analysis, specify positive controls and their pass threshold in the design document. Controls fail, investigate the platform; controls pass and the target does not, that is your result — write the negative finding.

"Not detected" is not "not expressed", and reviewers know the difference

Symptom: immunohistochemistry clearly shows the protein, but the transcriptome detects no mRNA. Two statements in the manuscript contradict each other and the review asks bluntly whether it is expressed or not.

Root cause: a signal below the limit of quantification only tells you this platform at this depth did not detect it — it does not support "not expressed". Protein half-lives are far longer than mRNA half-lives, so the two being out of step is normal rather than contradictory.

Fix: be strict in wording — write "mRNA below detection limit", never "not expressed" — and state the detection limit and sequencing depth in the methods. This is a textbook case for the wording-ceiling mechanism in bio-design: claim strength cannot exceed what the detection method supports.

A bar chart makes noise look like detection

Symptom: a standard bar chart, one signal clearly standing up as a bar. It reads as detected.

What is actually there: that signal has a raw count of 56, and the limit of quantification is 63 — it sits below noise. Bar charts start at zero, so any positive number renders as a bar with visible height, and nothing on the plot indicates it falls under the detection limit.

Fix: use a scatter plot for this kind of data and draw the LOQ as a horizontal reference line, so every point's position relative to that line is obvious. Replotted, the same data reads as "everything falls below the noise line" — the opposite of the impression the bar chart gave.

Same numbers, two plot types, two opposite conclusions. A figure is not decoration; it is part of the argument.

Do not dress a negative result up as a positive one

Symptom: the main result is negative, but the PI suggests "add a cell communication analysis" or "a network diagram would look better". A pile of attractive figures follows, and a reader skimming it comes away thinking the study is substantial — even though the core claim does not hold.

Why this is a problem: decorative analyses add no evidence, only misjudged confidence. They quietly perform "we did not find it" as "we found some things".

Fix: make "no decorative analyses on a negative result" a pre-registered rule. In real execution the cell-communication analyses across three rounds were skipped by rule and recorded as such — not forgotten, not permitted.

When a supervisor insists on a positive result

Symptom: the analysis comes back negative, but "negatives do not get published" pressure arrives, and the loosening begins — wider thresholds, different tests, selected subsets, until some combination yields p < 0.05.

A different framing: in a well-designed study, the negative is the answer — it closes off a mechanism the field widely assumed, so nobody has to walk that road again. The six studies in our case archive include several honestly reported negatives; one screened 1,915 plasma proteins to a mediating intersection of zero and still became a complete 8,060-word manuscript.

Fix: lock the acceptance criteria before the analysis (see section 02) and report the negative as a negative. What actually fails at review is not a negative result — it is a positive one obtained by adjustment after the fact.

Data verified 2026-08-11. All entries are pitfalls recorded in real development and analysis environments; elapsed times depend on hardware and data scale.

One cross-species annoyance deserves its own mention: gene symbols are not portable across species because naming conventions differ, so a direct intersection silently drops orthologues with different names and mismatches paralogues. Reviewers invariably ask how you mapped across species — you must use a dedicated orthologue mapping route such as biomaRt or the MGI vertebrate homology tables, and state the tool, version and retrieval date in your methods.

The problems in this section differ from those above: they are not technical failures within one analysis but structural issues across the field. The following come from public discussions in the bioinformatics community; the figures in brackets are how many people endorsed that view, which is some indication they are not isolated cases.

About 200 pipelines reviewed, roughly 15 actually reproducible

What the community said: a practitioner who reviews code for a living reported having looked at around 200 bioinformatics pipelines, of which perhaps 15 were genuinely reproducible (248 upvotes / 70 comments).

How it gets that way: hardcoded absolute paths, unpinned dependency versions, environments that only ever installed on the author's machine, script directories with no README. No single one is fatal; together they guarantee irreproducibility.

Fix: paths and environments cannot rely on individual discipline. A uniform project structure, a per-project exportable conda environment, automatically recorded parameters and version numbers — these have to be enforced by the framework, not written in a lab handbook and hoped for.

Code stays reproducible for exactly as long as its author stays in the job

What the community said: reproducibility has a lifespan matching how long the person who wrote the code stays in the same position (61 upvotes).

Why that stings: once they leave, nobody can read the variable names, the dependencies will not install, and the data paths all point into their home directory. Whoever inherits it usually rewrites rather than reuses — three months of work evaporating.

Fix: make "can this be restored" independent of any one person's memory. Analysis state, parameters and environment declarations all persist on disk and travel with the project, so what gets handed over is a project that reruns, not a folder full of scripts.

Nobody properly teaches software engineering to bioinformaticians

What the community said: nobody teaches bioinformaticians software engineering properly (73 upvotes); a follow-up comment added that because so few people teach it, "hardcoded paths" is not even recognised as a problem.

The real situation: most people came from biology or medicine, never learned version control, do not know what CI is, and manage environments by hand. This is a training gap, not an attitude problem.

Fix: clinical researchers should not have to complete a software engineering curriculum first. The reasonable approach is to build the practices into the workflow — you describe the analysis as usual while versions, seeds, dependencies and directory conventions are handled by the platform, without you having to learn them first.

Treating public datasets as "replicates" to pad the sample size

What the community said: someone described merging public RNA-seq datasets from different sources as replicates to make differential expression results "more robust", and called it indefensible (52 upvotes / 25 comments); a top reply added that the worse part is nobody reviews for it.

What is wrong with it: sequencing platforms, library preparation and sample handling all differ between studies, and the batch effect introduced by merging them is often an order of magnitude larger than the biological difference you are looking for. The sample size goes up while the conclusion becomes less trustworthy.

Fix: multi-dataset work requires batch correction with before-and-after diagnostics, and the methods section must state each dataset's origin and processing rather than "bioinformatics analysis was performed". See the batch-correction entry in section 03 for a real case where the signal was pushed down to the fifth principal component.

No matter how I tune single-cell parameters it comes out wrong — is it me?

What the community said: a post titled roughly "I have accepted that I am bad at single-cell analysis" drew 51 upvotes / 33 comments; the top reply argued single-cell analysis should at minimum be hypothesis-guided rather than aimless parameter tuning.

It is not you: a single-cell workflow has dozens of tunable parameters, and most tutorials give one set of defaults without explaining why. With no basis for judgment, tuning becomes guesswork.

Fix: settle the scientific question first and let parameters serve it; treat field-consensus values as a starting point rather than an answer, and run sensitivity checks on the decisions that matter (clustering resolution, QC thresholds). Struggling with parameters is usually a sign the question is not yet sharp, not that your technique is weak.

Six directions searched, all already published

Symptom: after settling on a methodological approach, six concrete entry points (inflammatory proteins, immune cells, gut microbiome, multi-omics, mitochondrial genes, programmed cell death) turned out to have all been systematically covered in PubMed.

The fix is not new keywords but a new causal direction: instead of asking "what causes this disease" (exposure to outcome), ask "what does this disease cause" (the reverse causal chain), which often opens a genuinely unoccupied window. Equally important, duplicate-checking must cover meta-analysis-equivalent publication formats such as network meta-analyses and pre-specified subgroup analyses.

The paper says the data is public; the download does nothing

Symptom: you build an entire study design off a published paper — research question, analysis route, figure plan all written — and only at the download step discover that "publicly available" means controlled access: an application, an ethics approval, a wait measured in months.

A real distribution: of four candidate datasets in one feasibility pre-search, access status came out as controlled / controlled / view-in-place only / genuinely open — one of four could be downloaded directly.

Fix: make data accessibility the first gate of the design rather than the last step. bio-design verifies during Phase 1, over the live network, whether each dataset exists and can actually be obtained — rather than relying on a model's recollection. Plenty of datasets that "should exist" either do not, or cannot be downloaded.

Three months in, it should have stopped on day one

Symptom: literature read, proposal written, grant application submitted, analysis begun with high hopes — and the detection rate is 0%. Three months of work blocked by something measurable on the first day.

How you could know on day one: run the minimum feasibility check first — do positive controls come through, is the target signal above the detection limit, is the sample size sufficient for the expected effect. In the section 04 example, three positive controls at 48%–68% against a target at 0% is a set of numbers available on day one.

Fix: state in the design what conditions should stop this study, and make it an executable verdict rather than a private expectation. Stopping a day early is far cheaper than being forced to stop three months in — and if fallback directions were written into the design too, the original data can usually be reused.

Why these belong at the design stage

Apart from the environment class, almost every pain point above shares one property: it surfaces after the analysis finishes, but is entirely foreseeable before the first line of code. Data leakage, small-sample metric traps, feature-selection ordering, multiple-comparison correction, overclaimed conclusions — these are recurring errors in the published literature, not novel surprises, and most are already named in reporting guidelines collected by the EQUATOR Network.

bio-design distils them into 546 trap warnings and 413 reviewer-perspective patterns and intercepts them during the design dialogue; bio-analyze encodes them as 20 error patterns and executable validators that block the workflow through exit codes. That is why the platform places its quality audit before biological interpretation rather than after it.